Showing results (191-200 of 286) with videos related to
Sort By:
Pageof 29
Oncology Letters|August 30, 2021
Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblastsMasahiro Samoto, Hideyasu Matsuyama, Hiroaki Matsumoto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2020
Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa ExpressionAzusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Foretinib Overcomes Entrectinib Resistance Associated with the <i>NTRK1</i> G667C Mutation in <i>NTRK1</i> Fusion-Positive Tumor Cells in a Brain Metastasis ModelAkihiro Nishiyama, Tadaaki Yamada, Kenji Kita, et al.International Journal of Molecular Sciences|June 20, 2019
Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the StomachNawaphat Jangphattananont, Hiroki Sato, Ryu Imamura, et al.Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.Journal of Pharmaceutical Health Care and Sciences|December 1, 2022
Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective studyHirofumi Nagai, Tsutomu Shimada, Yoshimitsu Takahashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2014
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutationJunya Nakade, Shinji Takeuchi, Takayuki Nakagawa, et al.Pancreas|July 19, 2014
Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancerKoushiro Ohtsubo, Tadaaki Yamada, Lu Zhao, et al.Cancer Medicine|January 14, 2022
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cellsYuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, et al.JOP : Journal of the Pancreas|September 11, 2013
Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiencyKoushiro Ohtsubo, Daisuke Ishikawa, Shigeki Nanjo, et al.Pageof 29